6 April 2022
BrandShield Systems plc
("BrandShield," the "Company," or the "Group")
Contract Win
BrandShield secures mandate with global pharmaceutical company
BrandShield Systems plc (AIM: BRSD), a leading provider of cybersecurity solutions for brand oriented digital risk protection, is pleased to announce that it has secured a new business contract with a leading pharmaceutical company ('the Client'). This comes as part of an ongoing growth in sales and the closing of several new customers since the beginning of 2022.
BrandShield will provide advanced brand protection for the Client, deploying its highly automated SaaS offering to identify and eradicate online threats, including fake pharmacies.
Geographically, BrandShield will focus on utilising its innovative software services to prevent cybercriminals across Asia and Oceania from jeopardising the Client's operations, alongside safeguarding users and improving the experience of the Client's customer base.
The mandate expands BrandShield's portfolio of pharmaceutical clients, which includes partnerships with the Pharmaceutical Security Institute and Bristol Myers Squibb, where BrandShield has leveraged its unique capabilities to detect and remove rogue pharmacies and fraudulent drug listings from the online space.
Yoav Keren, Chief Executive Officer of BrandShield, commented:
"This win is an example of one of several new mandates BrandShield has already secured in 2022, strengthening our reputation as a leading provider of digital risk protection solutions for companies across a wide array of sectors.
"BrandShield has a proven track record of successfully identifying and eradicating critical online threats to global pharmaceutical companies and we look forward to extending our leading position in the pharmaceutical space, one of many exciting opportunities in our pipeline for the near to medium term."
Enquiries:
| BrandShield Systems plc Yoav Keren, CEO
| +44 (0)20 3143 8300 |
| Spark Advisory Partners Limited (Nominated Adviser) Neil Baldwin / Andrew Emmott / James Keeshan
| +44 (0)20 3368 3554 |
| Shore Capital (Joint Broker) Toby Gibbs / James Thomas (Corporate Advisory) Henry Willcocks (Corporate Broking)
| +44 (0)20 7408 4090 |
| Tennyson Securities (Joint Broker) Peter Krens
| +44 (0)20 3368 3554 |
| Vigo Consulting (Financial Public Relations) Jeremy Garcia / Kendall Hill / Tara Benniman brandshield@vigoconsulting.com | +44 (0)20 7390 0237 |
About BrandShield
BrandShield is a leading cybersecurity company founded in Israel by cybersecurity experts that protect the world's largest brands and consumers from phishing attacks, online fraud, and other online threats posed by dangerous cybercriminals. Through its AI/ML platform, BrandShield identifies, tracks, and eliminates online threats for global brands and organizations, including Bristol Myers Squibb, Levi's, NewBalance, Swisscom, and the Pharmaceutical Security Institute. BrandShield is quoted on the London Stock Exchange AIM under ticker symbol BRSD. To learn more about BrandShield, please visit the company website at www.BrandShield.com.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.